• Partnering


IO Biotech is actively seeking partners to expand and broaden the development of our pipeline. We are interested in research collaborations and collaborations investigating synergistic effects of combining our compounds with other compounds in a pre-clinical or clinical setting. 

Our capabilities 

  • Broad pipeline of first-in-class immune modulating therapies
    • Dual-mode of action targeting both immune-suppressive cells and cancer cells expressing the target
    • Favorable safety profile as well as promising signs of efficacy
  • Unique and novel technology platform, T-Win
  • Robust IP estate for technology platform and compounds
  • High throughput and agile clinical development set-up
    • two completed phase I trials
    • two ongoing phase I trials
    • three planned phase I /phase II trials
  • Solid financial position funded by experienced investors
  • Experienced management team and world class scientific and clinical advisors

Upcoming partnering events

  • American Society of Clinical Oncology - ASCO, Chicago (June 2018)
  • BIO International, Boston (June 2018)

For more information, please contact 

Mikkel Dybkjaer

Senior Vice President, Business Development

e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.